CN115944598A - Allisartan isoproxil compound preparation and preparation method thereof - Google Patents
Allisartan isoproxil compound preparation and preparation method thereof Download PDFInfo
- Publication number
- CN115944598A CN115944598A CN202310041083.8A CN202310041083A CN115944598A CN 115944598 A CN115944598 A CN 115944598A CN 202310041083 A CN202310041083 A CN 202310041083A CN 115944598 A CN115944598 A CN 115944598A
- Authority
- CN
- China
- Prior art keywords
- allisartan isoproxil
- poloxamer
- pvp
- compound
- percent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 32
- -1 Allisartan isoproxil compound Chemical class 0.000 title abstract description 12
- XMHJQQAKXRUCHI-UHFFFAOYSA-N propan-2-yloxycarbonyloxymethyl 2-butyl-5-chloro-3-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate Chemical compound CCCCC1=NC(Cl)=C(C(=O)OCOC(=O)OC(C)C)N1CC1=CC=C(C=2C(=CC=CC=2)C2=NNN=N2)C=C1 XMHJQQAKXRUCHI-UHFFFAOYSA-N 0.000 claims abstract description 30
- 239000000314 lubricant Substances 0.000 claims abstract description 21
- 239000003381 stabilizer Substances 0.000 claims abstract description 21
- 239000000853 adhesive Substances 0.000 claims abstract description 16
- 230000001070 adhesive effect Effects 0.000 claims abstract description 16
- 239000003223 protective agent Substances 0.000 claims abstract description 16
- 239000007884 disintegrant Substances 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 11
- 239000002994 raw material Substances 0.000 claims abstract description 11
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 47
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 45
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 45
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 40
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 40
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 25
- 238000002156 mixing Methods 0.000 claims description 23
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 20
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 18
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 15
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 15
- 229920001983 poloxamer Polymers 0.000 claims description 15
- 229960000502 poloxamer Drugs 0.000 claims description 15
- 229920002472 Starch Polymers 0.000 claims description 14
- 239000008107 starch Substances 0.000 claims description 14
- 235000019698 starch Nutrition 0.000 claims description 14
- 239000008187 granular material Substances 0.000 claims description 13
- 239000002245 particle Substances 0.000 claims description 12
- 150000001875 compounds Chemical class 0.000 claims description 11
- HVWGGPRWKSHASF-UHFFFAOYSA-N Sulfuric acid, monooctadecyl ester Chemical compound CCCCCCCCCCCCCCCCCCOS(O)(=O)=O HVWGGPRWKSHASF-UHFFFAOYSA-N 0.000 claims description 10
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 10
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 claims description 10
- 229940043264 dodecyl sulfate Drugs 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 10
- LPTIRUACFKQDHZ-UHFFFAOYSA-N hexadecyl sulfate;hydron Chemical compound CCCCCCCCCCCCCCCCOS(O)(=O)=O LPTIRUACFKQDHZ-UHFFFAOYSA-N 0.000 claims description 10
- 235000019359 magnesium stearate Nutrition 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 10
- 238000012216 screening Methods 0.000 claims description 10
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 10
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 10
- 238000005507 spraying Methods 0.000 claims description 10
- 229940069328 povidone Drugs 0.000 claims description 7
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 5
- PAWALTXRSMCTAC-ODTHDHSBSA-N (2S)-2-[[(2R)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]propanoyl]amino]-3-hydroxypropanoyl]amino]-3-sulfanylpropanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-sulfanylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-sulfanylpropanoyl]amino]-3-(1H-imidazol-5-yl)propanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)CNC(=O)CN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](Cc1c[nH]cn1)C(O)=O PAWALTXRSMCTAC-ODTHDHSBSA-N 0.000 claims description 5
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 5
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 5
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 5
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 5
- 229920002307 Dextran Polymers 0.000 claims description 5
- 239000001856 Ethyl cellulose Substances 0.000 claims description 5
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 5
- 108010010803 Gelatin Proteins 0.000 claims description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 5
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 5
- 229920000881 Modified starch Polymers 0.000 claims description 5
- 239000004677 Nylon Substances 0.000 claims description 5
- 229920002507 Poloxamer 124 Polymers 0.000 claims description 5
- 229920002511 Poloxamer 237 Polymers 0.000 claims description 5
- 229920002517 Poloxamer 338 Polymers 0.000 claims description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims description 5
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 5
- 229920003080 Povidone K 25 Polymers 0.000 claims description 5
- 229920003081 Povidone K 30 Polymers 0.000 claims description 5
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 5
- 229920002125 Sokalan® Polymers 0.000 claims description 5
- 235000021355 Stearic acid Nutrition 0.000 claims description 5
- 229910000831 Steel Inorganic materials 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 5
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 5
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 5
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 5
- 238000009835 boiling Methods 0.000 claims description 5
- 229960001631 carbomer Drugs 0.000 claims description 5
- 239000004359 castor oil Substances 0.000 claims description 5
- 235000019438 castor oil Nutrition 0.000 claims description 5
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 5
- 229960000913 crospovidone Drugs 0.000 claims description 5
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 5
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 5
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 5
- 229920001249 ethyl cellulose Polymers 0.000 claims description 5
- 229960004667 ethyl cellulose Drugs 0.000 claims description 5
- 239000000945 filler Substances 0.000 claims description 5
- 229910021485 fumed silica Inorganic materials 0.000 claims description 5
- 229920000159 gelatin Polymers 0.000 claims description 5
- 239000008273 gelatin Substances 0.000 claims description 5
- 235000019322 gelatine Nutrition 0.000 claims description 5
- 235000011852 gelatine desserts Nutrition 0.000 claims description 5
- 239000008103 glucose Substances 0.000 claims description 5
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 5
- 238000005469 granulation Methods 0.000 claims description 5
- 230000003179 granulation Effects 0.000 claims description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 5
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 5
- 239000008101 lactose Substances 0.000 claims description 5
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims description 5
- 159000000003 magnesium salts Chemical class 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- 229920000609 methyl cellulose Polymers 0.000 claims description 5
- 239000001923 methylcellulose Substances 0.000 claims description 5
- 229960002900 methylcellulose Drugs 0.000 claims description 5
- 235000010981 methylcellulose Nutrition 0.000 claims description 5
- 229920001778 nylon Polymers 0.000 claims description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 5
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 5
- 239000003960 organic solvent Substances 0.000 claims description 5
- 229940093448 poloxamer 124 Drugs 0.000 claims description 5
- 229920001993 poloxamer 188 Polymers 0.000 claims description 5
- 229940044519 poloxamer 188 Drugs 0.000 claims description 5
- 229920001992 poloxamer 407 Polymers 0.000 claims description 5
- 229940044476 poloxamer 407 Drugs 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 5
- 229940068984 polyvinyl alcohol Drugs 0.000 claims description 5
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 5
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 5
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 5
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 5
- 239000000377 silicon dioxide Substances 0.000 claims description 5
- 235000012239 silicon dioxide Nutrition 0.000 claims description 5
- 239000002002 slurry Substances 0.000 claims description 5
- 235000010413 sodium alginate Nutrition 0.000 claims description 5
- 239000000661 sodium alginate Substances 0.000 claims description 5
- 229940005550 sodium alginate Drugs 0.000 claims description 5
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 5
- 159000000000 sodium salts Chemical class 0.000 claims description 5
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 5
- 239000007779 soft material Substances 0.000 claims description 5
- 239000000600 sorbitol Substances 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 5
- 239000008117 stearic acid Substances 0.000 claims description 5
- 239000010959 steel Substances 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- 239000000230 xanthan gum Substances 0.000 claims description 5
- 235000010493 xanthan gum Nutrition 0.000 claims description 5
- 229920001285 xanthan gum Polymers 0.000 claims description 5
- 229940082509 xanthan gum Drugs 0.000 claims description 5
- 241000220479 Acacia Species 0.000 claims description 4
- 235000010643 Leucaena leucocephala Nutrition 0.000 claims description 4
- 229960003943 hypromellose Drugs 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 229940032147 starch Drugs 0.000 claims 2
- 229920003109 sodium starch glycolate Polymers 0.000 claims 1
- 239000008109 sodium starch glycolate Substances 0.000 claims 1
- 229940079832 sodium starch glycolate Drugs 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 13
- 206010020772 Hypertension Diseases 0.000 abstract description 7
- 210000004369 blood Anatomy 0.000 abstract description 5
- 239000008280 blood Substances 0.000 abstract description 5
- 238000004090 dissolution Methods 0.000 abstract description 4
- 238000011282 treatment Methods 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 238000001727 in vivo Methods 0.000 abstract description 3
- 238000000034 method Methods 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- 108090000371 Esterases Proteins 0.000 abstract description 2
- 101800001442 Peptide pr Proteins 0.000 abstract description 2
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 abstract description 2
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 abstract description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 2
- 239000002207 metabolite Substances 0.000 abstract description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 11
- 230000002526 effect on cardiovascular system Effects 0.000 description 10
- 230000006872 improvement Effects 0.000 description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 2
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 2
- 208000009857 Microaneurysm Diseases 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000011866 long-term treatment Methods 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 210000004618 arterial endothelial cell Anatomy 0.000 description 1
- 210000002565 arteriole Anatomy 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001627 cerebral artery Anatomy 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 208000023589 ischemic disease Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention discloses an allisartan isoproxil compound preparation which is prepared from the following raw materials in parts by weight, including 25-55% of allisartan isoproxil, 0.15-0.5% of glidant, 0.2-13% of stabilizer, 4-35% of protective agent, 0.5-4.8% of adhesive, 5-28% of disintegrant and 0.2-3% of lubricant. Compared with the prior art, the invention has the advantages that: the invention can be used for preventing and/or treating hypertension and complications thereof, is also suitable for treating patients with cardiovascular diseases, and improves the compliance of the patients. The alisartan is an angiotensin II receptor antagonist, is a non-peptide precursor drug, and is completely hydrolyzed into a unique pharmacologically active metabolite EXP3174 by esterase in the process of in vivo gastrointestinal tract absorption; the embodiment of the invention can effectively ensure the disintegration and dissolution of the medicine, has stable dissolution rate level and can maintain stable blood concentration, thereby reducing the administration times, prolonging the administration interval and reducing the treatment cost.
Description
Technical Field
The invention relates to the technical field of medical medicines, in particular to an allisartan isoproxil compound preparation and a preparation method thereof.
Background
Cardiovascular and cerebrovascular diseases are the general names of cardiovascular diseases and cerebrovascular diseases, and generally refer to ischemic or hemorrhagic diseases of heart, brain and systemic tissues caused by hyperlipidemia, blood viscosity, atherosclerosis, hypertension and the like. Cardiovascular and cerebrovascular diseases are common diseases seriously threatening the health of human beings, particularly the middle-aged and elderly people over 50 years old, and even if the most advanced and perfect treatment means are applied at present, more than 50 percent of the survivors of cerebrovascular accidents can not take care of the life completely! The number of people dying from cardiovascular and cerebrovascular diseases every year in the world is as high as 1500 thousands of people, and the people live at the first position of various causes of death. Cardiovascular and cerebrovascular diseases become the first killer with the highest cause of death for human beings, and are also the soundless and violent in health of people! The cardiovascular and cerebrovascular diseases have the characteristics of high morbidity, high disability rate, high death rate, high recurrence rate and more complications, namely more than four high and more than one high.
The blood vessel wall of the cerebral artery of a person suffering from hypertension for a long time can be thickened or hardened, and the vessel cavity is thinned. When blood pressure rises suddenly, cerebral vessels are easy to rupture and cerebral hemorrhage occurs; or hardened cerebral arterioles form a chestnut-sized microaneurysm, and the microaneurysm breaks down when blood fluctuates, thereby causing cerebral hemorrhage; or the process of hypertension accelerating arteriosclerosis, arterial endothelial cell fluid is damaged, blood platelets are easy to gather at the injured part, and cerebral thrombus is easy to form, so that cardiovascular and cerebrovascular diseases are caused.
Modern life rhythm is tense, pressure of families and public institutions is higher, excessive drinking, too much food fat intake, lack of necessary exercise, pollution of living environment, rapid reduction of anion content in air, and insufficient anion intake in vivo, which directly result in slow metabolism speed of human body, slow blood flow speed, rapid rise of blood viscosity, and insufficient blood supply of heart and brain, and if the prevention and the regulation are not performed in time, cardiovascular and cerebrovascular diseases such as coronary heart disease, hypertension, cerebral thrombosis, fatty liver and the like can be caused.
Controlling blood pressure within a more ideal range is the key to preventing cardiovascular and cerebrovascular diseases. The data show that the incidence rate of cardiovascular and cerebrovascular diseases of hypertension patients insisting on long-term treatment is only 1/10 of that of patients who do not insist on treatment, namely, the cardiovascular and cerebrovascular diseases can be reduced by 90 percent as long as the blood pressure is insisted on for long term treatment.
Disclosure of Invention
The invention aims to overcome the defects of the technology and provides an allisartan isoproxil compound preparation and a preparation method thereof.
In order to solve the technical problems, the technical scheme provided by the invention is that the compound preparation of the allisartan isoproxil comprises the following components: the feed is prepared from the following raw materials in parts by weight: comprises 25 to 55 percent of allisartan isoproxil, 0.15 to 0.5 percent of glidant, 0.2 to 13 percent of stabilizer, 4 to 35 percent of protective agent, 0.5 to 4.8 percent of adhesive, 5 to 28 percent of disintegrant and 0.2 to 3 percent of lubricant.
As an improvement, the glidant is a mixture obtained by mixing one or more than two of magnesium stearate, fumed silica and talcum powder in any proportion.
As an improvement, the stabilizer is one or a mixture of more than two of hydroxypropyl methylcellulose, povidone, poloxamer, arabic gum, xanthan gum, sodium hyaluronate, sodium alginate, carbomer, polyvinyl alcohol, methylcellulose, ethylcellulose, hydroxypropyl methylcellulose, sodium carboxymethylcellulose and the like.
As an improvement, the hydroxypropyl methylcellulose in the stabilizer can be HPMC E3, HPMC E5, HPMC E6, HPMC E15 and HPMC E50, the povidone can be PVP K12, PVP K15, PVP K17, PVP K25, PVP K30, PVP K29/32, PVP K60 and PVP K120, and the poloxamer can be F68, poloxamer 124, poloxamer 188, poloxamer 237, poloxamer 338 and poloxamer 407.
The improvement is that the protective agent is one or a mixture of more than two of mannitol, glucose, sucrose, sorbitol, lactose, maltose, trehalose, dextran, dodecyl sulfate, hexadecyl sulfate, octadecyl sulfate and poloxamer
As an improvement, the dodecyl sulfate, hexadecyl sulfate and octadecyl sulfate are preferably sodium salt, potassium salt and magnesium salt.
As an improvement, the adhesive comprises one or a mixture of more of hydroxypropyl methylcellulose, hydroxypropyl cellulose, sodium carboxymethyl cellulose, povidone, starch slurry and gelatin.
As an improvement, the disintegrant comprises one or more of croscarmellose sodium, crospovidone, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, starch, pregelatinized starch, etc
As an improvement, the lubricant comprises one or a mixture of more than two of silicon dioxide, stearic acid, magnesium stearate, polyethylene glycol and hydrogenated castor oil.
A preparation method of an allisartan isoproxil compound preparation comprises the following steps:
s1, screening the allisartan isoproxil in parts by mass through a 120-mesh sieve, and screening other raw materials through a 100-mesh sieve according to the parts by mass for later use;
s2, dissolving the allisartan isoproxil, the stabilizer, the protective agent and the disintegrant into a proper amount of organic solvent to prepare a medicinal solution;
s3, placing the filler in the fluidized bed in parts by mass, spraying the medicine solution, performing fluidized bed spray granulation and drying, and adding the lubricant for mixing to obtain a mixed material;
s4, placing the mixed materials in a wet granulator, spraying an adhesive to prepare a soft material, and then granulating by using a 14-18-mesh nylon screen swing granulator;
s5, placing the prepared wet granules in a dryer, boiling and drying at the air inlet temperature of 55 ℃ to obtain dry granules;
s6, taking the dried particles, and grading the particles by adopting a 25-mesh steel sieve; after finishing the granules, adding a lubricant and a glidant, and mixing the mixture in a three-dimensional mixer for 25 to 35 minutes; and tabletting by adopting a rotary tablet press after mixing to obtain a finished product.
Compared with the prior art, the invention has the advantages that: 1. the invention can be used for preventing and/or treating hypertension and complications thereof, is also suitable for treating patients with cardiovascular diseases, and improves the compliance of the patients. The alisartan is an angiotensin II receptor antagonist, is a non-peptide precursor drug, and is completely hydrolyzed into a unique pharmacologically active metabolite EXP3174 by esterase in the process of in vivo gastrointestinal tract absorption;
2. the embodiment of the invention can effectively ensure the disintegration and dissolution of the medicine, has stable dissolution rate level and can maintain stable blood concentration, thereby reducing the administration times, prolonging the administration interval and reducing the treatment cost.
Detailed Description
The present invention is further described in detail below with reference to a medicament for treating rhinitis.
Example one
An allisartan isoproxil compound preparation: the composition is prepared from the following raw materials in parts by weight: comprises 25 percent of allisartan isoproxil, 0.15 percent of glidant, 0.2 percent of stabilizer, 4 percent of protective agent, 0.5 percent of adhesive, 5 percent of disintegrant and 0.2 percent of lubricant.
The blending ratio between the components is 1 part by mass of the allisartan isoproxil.
The glidant is a mixture obtained by mixing one or more of magnesium stearate, fumed silica and talcum powder in any proportion.
The stabilizer is one or more of hypromellose, polyvidone, poloxamer, acacia, xanthan gum, sodium hyaluronate, sodium alginate, carbomer, polyvinyl alcohol, methylcellulose, ethylcellulose, hydroxypropyl methylcellulose, sodium carboxymethylcellulose, etc.
The hydroxypropyl methylcellulose in the stabilizing agent can be HPMC E3, HPMC E5, HPMC E6, HPMC E15 and HPMC E50, the povidone can be PVP K12, PVP K15, PVP K17, PVP K25, PVP K30, PVP K29/32, PVP K60 and PVP K120, and the poloxamer can be F68, poloxamer 124, poloxamer 188, poloxamer 237, poloxamer 338 or poloxamer 407.
The protective agent is one or more of mannitol, glucose, sucrose, sorbitol, lactose, maltose, trehalose, dextran, dodecyl sulfate, hexadecyl sulfate, octadecyl sulfate, and poloxamer
The dodecyl sulfate, hexadecyl sulfate and octadecyl sulfate are preferably sodium salt, potassium salt and magnesium salt.
The adhesive comprises one or more of hydroxypropyl methylcellulose, hydroxypropyl cellulose, sodium carboxymethylcellulose, polyvidone, starch slurry and gelatin.
The disintegrant comprises one or more of croscarmellose sodium, crospovidone, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, starch, pregelatinized starch, etc
The lubricant comprises one or more of silicon dioxide, stearic acid, magnesium stearate, polyethylene glycol and hydrogenated castor oil.
A preparation method of an allisartan isoproxil compound preparation comprises the following steps:
s1, screening the allisartan isoproxil in parts by mass through a 120-mesh sieve, and screening other raw materials through a 100-mesh sieve according to the parts by mass for later use;
s2, dissolving the allisartan isoproxil, the stabilizing agent, the protective agent and the disintegrating agent in a proper amount of organic solvent to prepare a medicinal solution;
s3, placing the filler in the fluidized bed in parts by mass, spraying the medicine solution, performing fluidized bed spray granulation drying, and adding the lubricant for mixing to obtain a mixed material;
s4, placing the mixed materials in a wet granulator, spraying an adhesive to prepare a soft material, and then granulating by using a 14-18-mesh nylon screen swing granulator;
s5, placing the prepared wet particles in a dryer, and boiling and drying at the air inlet temperature of 55 ℃ to obtain dry particles;
s6, taking the dried particles, and finishing the particles by adopting a 25-mesh steel screen; after finishing the granules, adding a lubricant and a glidant, and mixing the mixture in a three-dimensional mixer for 25 to 35 minutes; and tabletting by adopting a rotary tablet press after mixing to obtain a finished product.
Example two
An allisartan isoproxil compound preparation: the feed is prepared from the following raw materials in parts by weight: comprises 40 percent of allisartan isoproxil, 0.3 percent of glidant, 6 percent of stabilizer, 19 percent of protective agent, 2.6 percent of adhesive, 16 percent of disintegrant and 1.6 percent of lubricant.
The blending ratio between the components is 1 part by mass of the allisartan isoproxil.
The glidant is a mixture obtained by mixing one or more than two of magnesium stearate, fumed silica and talcum powder in any proportion.
The stabilizer is one or more of hypromellose, polyvidone, poloxamer, acacia, xanthan gum, sodium hyaluronate, sodium alginate, carbomer, polyvinyl alcohol, methylcellulose, ethylcellulose, hydroxypropyl methylcellulose, sodium carboxymethylcellulose, etc.
The hydroxypropyl methylcellulose in the stabilizing agent can be HPMC E3, HPMC E5, HPMC E6, HPMC E15 and HPMC E50, the povidone can be PVP K12, PVP K15, PVP K17, PVP K25, PVP K30, PVP K29/32, PVP K60 and PVP K120, and the poloxamer can be F68, poloxamer 124, poloxamer 188, poloxamer 237, poloxamer 338 or poloxamer 407.
The protective agent is one or more of mannitol, glucose, sucrose, sorbitol, lactose, maltose, trehalose, dextran, dodecyl sulfate, hexadecyl sulfate, octadecyl sulfate, and poloxamer
The dodecyl sulfate, hexadecyl sulfate and octadecyl sulfate are preferably sodium salt, potassium salt and magnesium salt.
The adhesive comprises one or more of hydroxypropyl methylcellulose, hydroxypropyl cellulose, sodium carboxymethylcellulose, polyvidone, starch slurry and gelatin.
The disintegrant comprises one or more of croscarmellose sodium, crospovidone, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, starch, pregelatinized starch, etc
The lubricant comprises one or more of silicon dioxide, stearic acid, magnesium stearate, polyethylene glycol and hydrogenated castor oil.
A preparation method of an allisartan isoproxil compound preparation comprises the following steps:
s1, screening the allisartan isoproxil in parts by mass through a 120-mesh sieve, and screening other raw materials through a 100-mesh sieve according to the parts by mass for later use;
s2, dissolving the allisartan isoproxil, the stabilizer, the protective agent and the disintegrant into a proper amount of organic solvent to prepare a medicinal solution;
s3, placing the filler in the fluidized bed in parts by mass, spraying the medicine solution, performing fluidized bed spray granulation drying, and adding the lubricant for mixing to obtain a mixed material;
s4, placing the mixed materials in a wet granulator, spraying an adhesive to prepare a soft material, and then granulating by using a 14-18-mesh nylon screen swing granulator;
s5, placing the prepared wet granules in a dryer, boiling and drying at the air inlet temperature of 55 ℃ to obtain dry granules;
s6, taking the dried particles, and finishing the particles by adopting a 25-mesh steel screen; after finishing the granules, adding a lubricant and a flow aid, and placing the mixture into a three-dimensional mixer for mixing for 25 to 35 minutes; and tabletting by adopting a rotary tablet press after mixing to obtain a finished product.
EXAMPLE III
An allisartan isoproxil compound preparation: the composition is prepared from the following raw materials in parts by weight: comprises 55% of allisartan isoproxil, 0.5% of glidant, 13% of stabilizer, 35% of protective agent, 4.8% of adhesive, 28% of disintegrant and 3% of lubricant.
The blending ratio between the components is 1 part by mass of the allisartan isoproxil.
The glidant is a mixture obtained by mixing one or more than two of magnesium stearate, fumed silica and talcum powder in any proportion.
The stabilizer is one or more of hypromellose, polyvidone, poloxamer, acacia, xanthan gum, sodium hyaluronate, sodium alginate, carbomer, polyvinyl alcohol, methylcellulose, ethylcellulose, hydroxypropyl methylcellulose, sodium carboxymethylcellulose, etc.
The hydroxypropyl methylcellulose in the stabilizer can be HPMC E3, HPMC E5, HPMC E6, HPMC E15 and HPMC E50, the povidone can be PVP K12, PVP K15, PVP K17, PVP K25, PVP K30, PVP K29/32, PVP K60 and PVP K120, and the poloxamer can be F68, poloxamer 124, poloxamer 188, poloxamer 237, poloxamer 338 and poloxamer 407.
The protective agent is one or more of mannitol, glucose, sucrose, sorbitol, lactose, maltose, trehalose, dextran, dodecyl sulfate, hexadecyl sulfate, octadecyl sulfate, and poloxamer
The dodecyl sulfate, hexadecyl sulfate and octadecyl sulfate are preferably sodium salt, potassium salt and magnesium salt.
The adhesive comprises one or more of hydroxypropyl methylcellulose, hydroxypropyl cellulose, sodium carboxymethylcellulose, polyvidone, starch slurry and gelatin.
The disintegrant comprises one or more of croscarmellose sodium, crospovidone, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, starch, pregelatinized starch, etc
The lubricant comprises one or a mixture of more than two of silicon dioxide, stearic acid, magnesium stearate, polyethylene glycol and hydrogenated castor oil.
A preparation method of an allisartan isoproxil compound preparation comprises the following steps:
s1, screening the allisartan isoproxil in parts by mass through a 120-mesh sieve, and screening other raw materials through a 100-mesh sieve according to the parts by mass for later use;
s2, dissolving the allisartan isoproxil, the stabilizer, the protective agent and the disintegrant into a proper amount of organic solvent to prepare a medicinal solution;
s3, placing the filler in the fluidized bed in parts by mass, spraying the medicine solution, performing fluidized bed spray granulation drying, and adding the lubricant for mixing to obtain a mixed material;
s4, placing the mixed materials in a wet granulator, spraying an adhesive to prepare a soft material, and then granulating by using a 14-18-mesh nylon screen swing granulator;
s5, placing the prepared wet granules in a dryer, boiling and drying at the air inlet temperature of 55 ℃ to obtain dry granules;
s6, taking the dried particles, and finishing the particles by adopting a 25-mesh steel screen; after finishing the granules, adding a lubricant and a glidant, and mixing the mixture in a three-dimensional mixer for 25 to 35 minutes; and tabletting by adopting a rotary tablet press after mixing to obtain a finished product.
The present invention and the embodiments thereof have been described above, but the description is not limited thereto, and the embodiment shown is only one of the embodiments of the present invention, and the actual configuration is not limited thereto. In summary, those skilled in the art should appreciate that they can readily use the disclosed conception and specific embodiments as a basis for designing or modifying other structures for carrying out the same purposes of the present invention without departing from the spirit and scope of the invention as defined by the appended claims.
Claims (10)
1. The compound allisartan isoproxil preparation is characterized by being prepared from the following raw materials in parts by weight: comprises 25 to 55 percent of allisartan isoproxil, 0.15 to 0.5 percent of glidant, 0.2 to 13 percent of stabilizer, 4 to 35 percent of protective agent, 0.5 to 4.8 percent of adhesive, 5 to 28 percent of disintegrant and 0.2 to 3 percent of lubricant.
2. The compound allisartan isoproxil preparation according to claim 1, which is characterized in that: the glidant is a mixture obtained by mixing one or more of magnesium stearate, fumed silica and talcum powder in any proportion.
3. The compound allisartan isoproxil preparation according to claim 1, which is characterized in that: the stabilizer is one or more of hypromellose, polyvidone, poloxamer, acacia, xanthan gum, sodium hyaluronate, sodium alginate, carbomer, polyvinyl alcohol, methylcellulose, ethylcellulose, hydroxypropyl methylcellulose, sodium carboxymethylcellulose, etc.
4. The compound allisartan isoproxil preparation according to claim 3, which is characterized in that: the hydroxypropyl methylcellulose in the stabilizing agent can be HPMC E3, HPMC E5, HPMC E6, HPMC E15 and HPMC E50, the povidone can be PVP K12, PVP K15, PVP K17, PVP K25, PVP K30, PVP K29/32, PVP K60 and PVP K120, and the poloxamer can be F68, poloxamer 124, poloxamer 188, poloxamer 237, poloxamer 338 or poloxamer 407.
5. The compound allisartan isoproxil preparation according to claim 1, which is characterized in that: the protective agent is one or a mixture of more than two of mannitol, glucose, sucrose, sorbitol, lactose, maltose, trehalose, dextran, dodecyl sulfate, hexadecyl sulfate, octadecyl sulfate and poloxamer.
6. The compound allisartan isoproxil preparation according to claim 5, which is characterized in that: the dodecyl sulfate, hexadecyl sulfate and octadecyl sulfate are preferably sodium salt, potassium salt and magnesium salt.
7. The compound allisartan isoproxil preparation according to claim 1, which is characterized in that: the adhesive comprises one or more of hydroxypropyl methylcellulose, hydroxypropyl cellulose, sodium carboxymethylcellulose, polyvidone, starch slurry and gelatin.
8. The compound allisartan isoproxil preparation according to claim 1, which is characterized in that: the disintegrant comprises one or more of croscarmellose sodium, crospovidone, sodium starch glycolate, low-substituted hydroxypropyl cellulose, starch, pregelatinized starch, etc.
9. The compound allisartan isoproxil preparation according to claim 1, which is characterized in that: the lubricant comprises one or more of silicon dioxide, stearic acid, magnesium stearate, polyethylene glycol and hydrogenated castor oil.
10. The preparation method of the compound allisartan isoproxil preparation is characterized by comprising the following steps:
s1, screening the allisartan isoproxil in parts by mass through a 120-mesh sieve, and screening other raw materials through a 100-mesh sieve according to the parts by mass for later use;
s2, dissolving the allisartan isoproxil, the stabilizing agent, the protective agent and the disintegrating agent in a proper amount of organic solvent to prepare a medicinal solution;
s3, placing the filler in the fluidized bed in parts by mass, spraying the medicine solution, performing fluidized bed spray granulation drying, and adding the lubricant for mixing to obtain a mixed material;
s4, placing the mixed materials in a wet granulator, spraying an adhesive to prepare a soft material, and then granulating by using a 14-18-mesh nylon screen swing granulator;
s5, placing the prepared wet granules in a dryer, boiling and drying at the air inlet temperature of 55 ℃ to obtain dry granules;
s6, taking the dried particles, and finishing the particles by adopting a 25-mesh steel screen; after finishing the granules, adding a lubricant and a glidant, and mixing the mixture in a three-dimensional mixer for 25 to 35 minutes; and tabletting by adopting a rotary tablet press after mixing to obtain a finished product.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310041083.8A CN115944598A (en) | 2023-01-13 | 2023-01-13 | Allisartan isoproxil compound preparation and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310041083.8A CN115944598A (en) | 2023-01-13 | 2023-01-13 | Allisartan isoproxil compound preparation and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115944598A true CN115944598A (en) | 2023-04-11 |
Family
ID=87282496
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310041083.8A Pending CN115944598A (en) | 2023-01-13 | 2023-01-13 | Allisartan isoproxil compound preparation and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115944598A (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107441048A (en) * | 2016-05-31 | 2017-12-08 | 深圳信立泰药业股份有限公司 | A kind of A Lishatan esters pharmaceutical composition and the preparation containing the pharmaceutical composition and preparation method thereof |
-
2023
- 2023-01-13 CN CN202310041083.8A patent/CN115944598A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107441048A (en) * | 2016-05-31 | 2017-12-08 | 深圳信立泰药业股份有限公司 | A kind of A Lishatan esters pharmaceutical composition and the preparation containing the pharmaceutical composition and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11389428B2 (en) | Controlled-release melatonin compositions and related methods | |
AU2019268052B2 (en) | Pharmaceutical composition containing dimethyl fumarate for administration at a low daily dose | |
ES2347968T3 (en) | SOLID PREPARATION THAT DISAPPEARS RAPIDLY. | |
RU2616516C2 (en) | Pharmaceutical composition containing olmesartan medoxomil and rosuvastatin or its salt | |
BR112020024125A2 (en) | pharmaceutical combination, composition and preparation of compound comprising glucokinase activator and dpp-iv inhibitor, and method of preparation and use thereof | |
US9278063B2 (en) | Press-coated orally-disintegrating tablets | |
KR20090065524A (en) | Programmable buoyant delivery technology | |
AU2002318155B8 (en) | Solid pharmaceutical formulations comprising modafinil | |
RU2466717C2 (en) | Pharmaceutical solid preparation containing benzazepin and method for preparing it | |
JPWO2011019043A1 (en) | Intraoral quick disintegrating tablet containing two or more kinds of particles | |
JP2009542647A (en) | Memantine pharmaceutical composition | |
JPWO2006080481A1 (en) | Multiple unit type oral sustained-release preparation and method for producing the same | |
US5814339A (en) | Film coated tablet of paracetamol and domperidone | |
JP5479909B2 (en) | New formulation | |
EP2554159A1 (en) | Dosage forms comprising apixaban and content uniformity enhancer | |
CA2498506C (en) | Novel pharmaceutical formulations of modafinil | |
US20120010216A1 (en) | Pharmaceutical compositions containing vanoxerine | |
WO2012029838A1 (en) | Orally disintegrating tablet | |
CN102727456B (en) | Drug port cavity disintegrating tablet and preparation method thereof | |
CN115944598A (en) | Allisartan isoproxil compound preparation and preparation method thereof | |
KR102409102B1 (en) | pharmaceutical composition | |
JPWO2017038455A1 (en) | Super-fast disintegrating tablet and method for producing the same | |
JP2020196713A (en) | Edoxaban-containing orally disintegrating tablet | |
JP4808612B2 (en) | Composition for oral administration containing alkylenedioxybenzene derivative | |
US20080194560A1 (en) | Disintegration promoters in solid dose wet granulation formulations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |